STOCK TITAN

Bellicum Pharmaceuticals, Inc. - $BLCM STOCK NEWS

Welcome to our dedicated page for Bellicum Pharmaceuticals news (Ticker: $BLCM), a resource for investors and traders seeking the latest updates and insights on Bellicum Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bellicum Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bellicum Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.77%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.21%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
Bellicum Pharmaceuticals, Inc.

Nasdaq:BLCM

BLCM Rankings

BLCM Stock Data

778.33k
6.78M
0.99%
32.91%
15.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Houston

About BLCM

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.